Barclays Rates Bristol-Myers Squibb Overweight Citing FY26 Pipeline Growth Prospects
Barclays initiated U.S. large-cap biopharma coverage with a Neutral industry view and Overweight rating on Bristol-Myers Squibb, citing emerging pipeline green shoots despite a significant patent cliff. Analysts anticipate upward estimate revisions and multiple expansion for BMY as new clinical data and pipeline assets materialize throughout FY26.
1. Coverage Initiation by Barclays
Barclays launched U.S. large-cap biopharma coverage with a Neutral industry view and selected Bristol-Myers Squibb as one of four preferred picks, highlighting the sector’s defensive qualities and improved U.S. policy clarity following most-favored-nation agreements.
2. Overweight Rating and Pipeline Rationale
Despite facing a significant patent cliff, analysts assigned Bristol-Myers Squibb an Overweight rating, pointing to ‘green shoots’ from its late-stage pipeline that could help offset revenue declines as key drug patents expire.
3. FY26 Catalyst Timeline and AI Tailwinds
Analysts expect multiple clinical readouts and new asset data in FY26 to drive upward estimate revisions and multiple expansion for Bristol-Myers Squibb, while AI-driven R&D efficiencies—such as 30% clinical trial cost gains—offer an additional growth tailwind.